OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced Shionogi Inc., a New Jersey-based ...
In their research article published in Eurosurveillance, von Schreeb et al. challenge existing assumptions regarding the relationship between the use of HIV pre-exposure prophylaxis (PrEP) and the ...
1. Pre-exposure prophylaxis clinical trials of a 3-dose regimen of Verorab ® followed by a booster dose at 1 year in adults and children achieved an adequate immune response. 1 2. Of those who had a ...
HIV pre-exposure prophylaxis (PrEP) is an effective and safe intervention for individuals with behaviors that are considered high risk for acquiring HIV infection. Despite the success of this ...
MONTRÉAL, March 25, 2025 /CNW/ - ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (PFE) and Shionogi as shareholders, is pleased to ...
HIV (human immunodeficiency virus) is a virus that attacks the body's immune system. 5 HIV is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex ...